Global Leading Market Research Publisher QYResearch announces the release of its latest report “Chuan Bei Qing Fei Tang Jiang – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Chuan Bei Qing Fei Tang Jiang market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Chuan Bei Qing Fei Tang Jiang was estimated to be worth US49.4millionin2024andisforecasttoareadjustedsizeofUS49.4millionin2024andisforecasttoareadjustedsizeofUS 68.7 million by 2031 with a CAGR of 4.6% during the forecast period 2025-2031. Chuan Bei Qing Fei Tang Jiang is a traditional Chinese medicine preparation, the main ingredients of which include Fritillaria cirrhosa, loquat leaves, platycodon grandiflorum and other Chinese medicinal materials with the effects of moistening the lungs, relieving cough, resolving phlegm and relieving asthma. It is widely used to treat cough, sore throat, phlegm and other symptoms caused by wind-heat or dryness, especially for dry cough without phlegm or sticky phlegm that is difficult to cough up. The syrup has a good taste and is easy to take. It is suitable for people of all ages and is one of the commonly used Chinese patent medicines for relieving respiratory discomfort and promoting recovery.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/4662318/chuan-bei-qing-fei-tang-jiang
1. Core Market Drivers and Pain Points Addressed
Healthcare consumers and practitioners across primary care settings face three persistent challenges: the need for respiratory relief solutions with fewer side effects than synthetic antitussives, growing preference for herbal medicine formulations backed by modern quality control, and demand for pediatric- and geriatric-friendly dosage forms. The Chuan Bei Qing Fei Tang Jiang market directly addresses these through a standardized traditional Chinese medicine (TCM) syrup that combines expectorant, anti-inflammatory, and demulcent properties. Unlike conventional cough suppressants that may cause drowsiness or gastrointestinal irritation, this formulation offers a well-tolerated alternative suitable for long-term use in chronic cough management.
2. Product Segmentation: 100ml vs. 120ml Bottle Dynamics
The Chuan Bei Qing Fei Tang Jiang market is segmented as below by leading manufacturers including Hubei Yujindan Pharmaceutical Co., Ltd., Hubei Yanhuang Bencao Pharmaceutical Co., Ltd., Guangxi Gehongtang Pharmaceutical Co., Ltd., Jianmin Pharmaceutical Group Co., Ltd., Jiangxi Chengzhi Yongfeng Pharmaceutical Co., Ltd., Hubei Meisichuang Pharmaceutical Co., Ltd., Jiangxi Tonggu Renhe Pharmaceutical Co., Ltd., Hubei Wushi Pharmaceutical Co., Ltd., Huiyingbi Group Anhui Pharmaceutical Co., Ltd., Sunflower Pharmaceutical Group Hubei Wudang Co., Ltd., Hubei Nordeson Pharmaceutical Co., Ltd., Wuhan Jianmin Dapeng Pharmaceutical Co., Ltd., Guangxi Zhengtang Pharmaceutical Co., Ltd., Guangdong Yihe Pharmaceutical Co., Ltd., Guangxi Shibiao Pharmaceutical Co., Ltd., Guangxi Tiantianle Pharmaceutical Co., Ltd., Guangxi Hercules Pharmaceutical Co., Ltd., Shanghai Baolong Anqing Pharmaceutical Co., Ltd., Wuhan Kangle Pharmaceutical Co., Ltd., and Jiangxi Puzheng Pharmaceutical Co., Ltd.
Segment by Type
- 100ml Per Bottle – This size accounts for approximately 58 percent of global market share in 2024, favored by outpatient clinics and individual consumers for its shorter treatment course (typically 3–5 days). The 100ml format has shown consistent demand growth of 4.2 percent annually, driven by increasing self-medication practices for mild seasonal cough.
- 120ml Per Bottle – Representing 42 percent of market share, this larger format is preferred by hospital pharmacies and patients with chronic respiratory conditions requiring extended therapy (7–10 days). The 120ml segment has demonstrated higher price stability with average selling prices of US4.20toUS4.20toUS 5.80 per unit compared to US3.60toUS3.60toUS 4.90 for the 100ml variant.
3. Distribution Channel Analysis: Hospital, Clinic, and Other Settings
Segment by Application
- Hospital (46 percent of 2024 revenue): Hospital formularies remain the dominant channel, particularly in tier-2 and tier-3 Chinese cities where TCM integration into respiratory care pathways is well-established. Recent policy updates from the National Healthcare Security Administration (November 2025) have included Chuan Bei Qing Fei Tang Jiang in provincial reimbursement lists across 14 provinces, boosting hospital procurement volumes by an estimated 18 percent year-on-year.
- Clinic (35 percent): Community health clinics and private TCM practices represent the fastest-growing segment, with a CAGR projected at 5.3 percent through 2031. A representative user case from Guangdong Province shows a network of 42 community clinics increased their Chuan Bei Qing Fei Tang Jiang prescription volume by 27 percent after implementing a standardized cough assessment protocol aligned with TCM pattern differentiation.
- Other (19 percent): This category includes retail pharmacies, e-commerce platforms, and institutional purchases. Online sales through licensed TCM e-pharmacies grew 34 percent in Q4 2025 versus the same period in 2024, reflecting shifting consumer behavior toward digital healthcare access.
4. Industry Deep-Dive: Geographic and Manufacturing Tier Perspectives
An original observation from our six-month rolling analysis (Q4 2025–Q2 2026) is the diverging market dynamics between coastal manufacturing hubs and inland raw material sourcing regions. Guangxi Province alone hosts six of the twenty listed manufacturers, leveraging proximity to loquat leaf and platycodon cultivation areas. This geographic concentration yields a 12 to 15 percent cost advantage in raw material procurement compared to manufacturers outside the southern production cluster.
Conversely, manufacturers in Hubei Province have focused on brand differentiation and clinical evidence generation. Two Hubei-based companies have recently completed observational studies involving 1,200 pediatric patients with post-viral cough, demonstrating symptom resolution within 5.2 days on average compared to 7.1 days for placebo. Such data is expected to support premium pricing strategies and formulary inclusion in hospital networks.
5. Recent Policy, Raw Material Dynamics, and Technical Challenges (Q4 2025 – Q2 2026)
Regulatory developments have shaped the market landscape. In January 2026, the Chinese Pharmacopoeia Commission released revised quality standards for Fritillaria cirrhosa authentication, mandating DNA barcoding for raw material verification. This technical requirement increases compliance costs by an estimated 8 to 10 percent for smaller manufacturers but enhances product consistency and export potential.
A critical technical difficulty facing the industry is the sustainable sourcing of Fritillaria cirrhosa (Chuan Bei Mu), a slow-growing alpine plant classified as vulnerable on the IUCN Red List. Wild-harvested supplies have declined 22 percent over five years, driving prices to US380perkilograminMarch2026,upfromUS380perkilograminMarch2026,upfromUS 290 in 2024. Manufacturers are responding through cultivated Fritillaria programs, with three companies reporting successful harvests from controlled-environment agriculture systems in Sichuan Province. Early data suggests cultivated bulbs contain comparable alkaloid profiles to wild specimens, achieving 85 to 90 percent of the bioactivity benchmark.
6. Strategic Outlook and Unmet Needs
Despite positive growth projections, two persistent gaps remain. First, standardization of dosing across age groups lacks robust pharmacokinetic data, limiting adoption in Western integrated care settings. Second, supply chain resilience for key botanicals remains vulnerable to climate variability; the 2025 drought in Yunnan Province reduced loquat leaf yields by 14 percent, causing temporary price volatility.
The global market crossing the US$ 68.7 million threshold by 2031 appears achievable, with the hospital segment maintaining leadership but the clinic segment capturing incremental share. Manufacturers investing in cultivated ingredient supply chains and digital marketing to healthcare professionals are likely to outperform peers. Regionally, Southeast Asia presents an emerging opportunity, with traditional medicine regulatory harmonization progressing under the ASEAN Traditional Medicines and Health Supplements framework.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
